Clinical Trial Update: Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial examining Erlotinib treatment beyond progression in EGFR-mutant non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ERLOTINIB (Erlotinib)

Snippet

Sponsor: Finnish Lung Cancer Group | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED